CTOs on the Move

Amphastar Pharmaceuticals

www.amphastar.com

 
Amphastar Pharmaceuticals, Inc. is a generic and specialty pharmaceutical company that is engaged in the discovery, development, manufacture and marketing of generic and proprietary pharmaceuticals, innovative delivery systems and active pharmaceutical
  • Number of Employees: 100-250
  • Annual Revenue: $50-100 Million

Executives

Name Title Contact Details

Similar Companies

Anda Inc

Anda Inc is a Fort Lauderdale, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Y Prime

The process that we follow for all projects is simple: we translate real-world experiences into expert advice. Whether this is through consulting or software applications, we align our entire organization to help you solve the specifics of challenges faced. When organizations engage with Y Prime, they have a dedicated support team that never changes. The people you work with from Day 1 will be there until completion of your project – no “knowledge transfers,” or redundant personnel required.  

Kenney Orthopedics

Restoring Motion – Empowering Lives. Kenney Orthopedics, LLC, is committed to providing quality orthopedic and prosthetic related products and services.

Alyvant

Using data to connect patients to therapies that better benefit them.

Cerebral

At Cerebral, we`re on a mission to democratize access to high-quality mental health care. We believe that everyone everywhere deserves to get the care they need, and are striving to make care convenient and accessible, while tackling the stigmas that surround mental illness. Since launching in January 2020, we have gone from a team of 5 to over 4,000 across the United States. With support from investors like SoftBank, Silver Lake, Access Industries, Bill Ackman, WestCap, and others, and impactful leaders like you, we`ll continue to democratize mental health care and double down on clinical quality and deliver exceptional patient outcomes for years to come. With a heavy focus on clinical quality and safety in all that we do, we`ve accomplished excellent patient outcomes: • 82% of patients report an improvement in their anxiety symptoms after using Cerebral. • 75% of patients who report improvement in their depression see improvement within 60 days. • 50% of patients who initially report suicidal ideation no longer harbor suicidal thoughts after treatment with Cerebral. This is just the beginning for Cerebral, and we won`t stop building, growing, and iterating until everyone, everywhere can access high-quality evidence-based mental health care without high costs and/or long wait times. We`re looking for mission-driven leaders who share these values, and we need your help as we transform access to high-quality mental health care in the United States and beyond.